KR101800140B1 - 벤조티아졸론 화합물 - Google Patents

벤조티아졸론 화합물 Download PDF

Info

Publication number
KR101800140B1
KR101800140B1 KR1020167007782A KR20167007782A KR101800140B1 KR 101800140 B1 KR101800140 B1 KR 101800140B1 KR 1020167007782 A KR1020167007782 A KR 1020167007782A KR 20167007782 A KR20167007782 A KR 20167007782A KR 101800140 B1 KR101800140 B1 KR 101800140B1
Authority
KR
South Korea
Prior art keywords
compound
formula
ylamino
butoxyphenyl
thiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167007782A
Other languages
English (en)
Korean (ko)
Other versions
KR20160038079A (ko
Inventor
준 카오
베른하르트 에르브
로빈 알렉 페어허스트
아르노 그항듀히
신지 하다키야마
막달레나 코지크자크-홀브로
신종 라이
필리프 루스텐베르거
베른트 리베젤
니콜라 투필리
토마스 울리치
시앙 우
지안구앙 주
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47010668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101800140(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20160038079A publication Critical patent/KR20160038079A/ko
Application granted granted Critical
Publication of KR101800140B1 publication Critical patent/KR101800140B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Emergency Medicine (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167007782A 2011-09-06 2012-09-05 벤조티아졸론 화합물 Expired - Fee Related KR101800140B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2011/079379 2011-09-06
CN2011079379 2011-09-06
PCT/IB2012/054580 WO2013035047A1 (en) 2011-09-06 2012-09-05 Benzothiazolone compound

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147008777A Division KR101628585B1 (ko) 2011-09-06 2012-09-05 벤조티아졸론 화합물

Publications (2)

Publication Number Publication Date
KR20160038079A KR20160038079A (ko) 2016-04-06
KR101800140B1 true KR101800140B1 (ko) 2017-11-21

Family

ID=47010668

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167007782A Expired - Fee Related KR101800140B1 (ko) 2011-09-06 2012-09-05 벤조티아졸론 화합물
KR1020147008777A Expired - Fee Related KR101628585B1 (ko) 2011-09-06 2012-09-05 벤조티아졸론 화합물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147008777A Expired - Fee Related KR101628585B1 (ko) 2011-09-06 2012-09-05 벤조티아졸론 화합물

Country Status (39)

Country Link
US (6) US8933108B2 (https=)
EP (1) EP2753609B1 (https=)
JP (2) JP6130835B2 (https=)
KR (2) KR101800140B1 (https=)
CN (2) CN103781771B (https=)
AP (1) AP3830A (https=)
AR (1) AR087787A1 (https=)
AU (1) AU2013200422C1 (https=)
BR (1) BR112014004732A2 (https=)
CA (1) CA2845766A1 (https=)
CL (1) CL2014000493A1 (https=)
CO (1) CO6900147A2 (https=)
CR (1) CR20140114A (https=)
CU (1) CU24303B1 (https=)
CY (1) CY1118585T1 (https=)
DK (1) DK2753609T3 (https=)
EA (1) EA022909B1 (https=)
ES (1) ES2615052T3 (https=)
GT (1) GT201400042A (https=)
HR (1) HRP20170075T1 (https=)
HU (1) HUE030530T2 (https=)
IL (1) IL231235A (https=)
JO (1) JO3192B1 (https=)
LT (1) LT2753609T (https=)
MX (1) MX345405B (https=)
MY (1) MY163301A (https=)
PE (1) PE20141993A1 (https=)
PH (1) PH12014500399A1 (https=)
PL (1) PL2753609T3 (https=)
PT (1) PT2753609T (https=)
RS (1) RS55468B1 (https=)
SG (1) SG2014013114A (https=)
SI (1) SI2753609T1 (https=)
TN (1) TN2014000060A1 (https=)
TW (1) TWI555738B (https=)
UA (1) UA114295C2 (https=)
UY (1) UY34312A (https=)
WO (1) WO2013035047A1 (https=)
ZA (2) ZA201401112B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
DK2890687T3 (en) * 2012-08-30 2017-10-09 Novartis Ag Salts of benzothiazolone compound as beta-2-adrenoceptor agonist
ES2646916T3 (es) 2012-11-19 2017-12-18 Bayer Pharma Aktiengesellschaft Aminoimidazopiridazinas como inhibidores de MKNK1 cinasa
EP2961391B1 (en) * 2013-02-28 2017-05-17 Novartis AG Formulation comprising benzothiazolone compound
US10967119B1 (en) 2019-04-01 2021-04-06 Azizi Bilal Wearable medication injecting device

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006056471A1 (en) 2004-11-29 2006-06-01 Novartis Ag 5-hydroxy-benzothiazole derivatives having beta-2-adrenorecptor agonist activity

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308157B1 (en) * 1987-09-15 1997-02-26 The Rowett Research Institute Therapeutic applications of beta-adrenergic agonists
US20070082918A1 (en) * 1993-11-02 2007-04-12 Naftchi N E Neurologically active compounds and compounds with multiple activities
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
WO1999009018A1 (en) 1997-08-14 1999-02-25 Kirin Beer Kabushiki Kaisha BENZOTHIAZOLONE DERIVATIVES HAVING SELECTIVE β2 RECEPTOR AGONIST ACTIVITY
EP1144387A1 (en) 1998-12-04 2001-10-17 Neurosearch A/S New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6872723B2 (en) * 2002-01-28 2005-03-29 Wyeth Stabilized difloxacin injectable solution
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US6743797B2 (en) * 2002-02-22 2004-06-01 Chantest, Inc. Methods for treating cardiac arrhythmia
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PE20050130A1 (es) 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
JP2006521201A (ja) * 2003-03-26 2006-09-21 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 鏡像異性体富化したアルコール類およびアミン類を製造する方法
WO2004087142A1 (en) * 2003-04-04 2004-10-14 Novartis Ag Quinoline-2-one-derivatives for the treatment of airways diseases
JP2007503472A (ja) * 2003-06-10 2007-02-22 カリプシス・インコーポレーテッド 病気治療用のヒストン脱アセチル化酵素阻害剤としてのカルボニル化合物
AU2004247136A1 (en) 2003-06-10 2004-12-23 Kalypsys, Inc. Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
JP2009513531A (ja) 2003-07-11 2009-04-02 グラクソ グループ リミテッド 糖エステルを含む吸入可能医薬製剤
JP2009514779A (ja) 2003-07-11 2009-04-09 グラクソ グループ リミテッド 医薬製剤
US7345060B2 (en) 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
GB0328490D0 (en) 2003-12-09 2004-01-14 Glaxo Group Ltd Medicinal compounds
JP2005187357A (ja) 2003-12-25 2005-07-14 Nippon Suisan Kaisha Ltd 選択的なβ２受容体アゴニスト活性を有するベンゾチアゾロン誘導体の製造方法
GB0402797D0 (en) * 2004-02-09 2004-03-10 Novartis Ag Organic compounds
CA2565243A1 (en) 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases
EP1595873A1 (de) 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen
WO2006014704A1 (en) 2004-07-21 2006-02-09 Theravance, Inc. DIARYL ETHER β2 ADRENERGIC RECEPTOR AGONISTS
DE102004045648A1 (de) 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
TW200740781A (en) 2005-08-29 2007-11-01 Astrazeneca Ab Novel compounds
TW200738659A (en) 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
WO2007086078A2 (en) 2006-01-30 2007-08-02 Panacea Biotec Ltd. Novel pharmaceutical compositions and process of preparation thereof
MX2008010187A (es) 2006-02-10 2008-10-31 Summit Corp Plc Tratamiento de distrofia muscular de duchenne.
TW200745084A (en) 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP2064174B1 (en) * 2006-08-10 2016-10-26 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Preparation of (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure
TW200833670A (en) * 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
JP2010535708A (ja) 2007-08-03 2010-11-25 ビオマリン アイジーエー リミテッド デュシェンヌ型筋ジストロフィーの治療のための薬物併用
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
GB0814728D0 (en) 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
GB0823140D0 (en) 2008-12-18 2009-01-28 Astrazeneca Ab New combination
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
DK2890687T3 (en) * 2012-08-30 2017-10-09 Novartis Ag Salts of benzothiazolone compound as beta-2-adrenoceptor agonist
EP2961391B1 (en) 2013-02-28 2017-05-17 Novartis AG Formulation comprising benzothiazolone compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006056471A1 (en) 2004-11-29 2006-06-01 Novartis Ag 5-hydroxy-benzothiazole derivatives having beta-2-adrenorecptor agonist activity
US20080096940A1 (en) 2004-11-29 2008-04-24 Fairhurst Robin A 5-Hydroxy-Benzothiazole Derivatives Having Beta-2-Adrenoreceptor Agonist Activity

Also Published As

Publication number Publication date
CL2014000493A1 (es) 2014-10-03
LT2753609T (lt) 2017-01-10
CN106187942B (zh) 2020-06-26
IL231235A (en) 2017-09-28
DK2753609T3 (en) 2017-02-06
HUE030530T2 (en) 2017-05-29
US10251868B2 (en) 2019-04-09
JP2017132781A (ja) 2017-08-03
EP2753609A1 (en) 2014-07-16
TWI555738B (zh) 2016-11-01
AR087787A1 (es) 2014-04-16
JP6130835B2 (ja) 2017-05-17
US20180140582A1 (en) 2018-05-24
JO3192B1 (ar) 2018-03-08
CN103781771B (zh) 2016-08-24
KR101628585B1 (ko) 2016-06-08
CR20140114A (es) 2014-05-06
JP2014525472A (ja) 2014-09-29
UA114295C2 (uk) 2017-05-25
ES2615052T3 (es) 2017-06-05
PH12014500399A1 (en) 2021-06-02
JP6340103B2 (ja) 2018-06-06
US20160075670A1 (en) 2016-03-17
EA201490573A1 (ru) 2014-06-30
UY34312A (es) 2013-04-30
AU2013200422A1 (en) 2013-03-21
US20150094346A1 (en) 2015-04-02
IL231235A0 (en) 2014-04-30
US20160279107A1 (en) 2016-09-29
US9913828B2 (en) 2018-03-13
AU2013200422B2 (en) 2014-08-07
CU20140028A7 (es) 2014-05-27
AP3830A (en) 2016-09-30
EA022909B1 (ru) 2016-03-31
KR20140057382A (ko) 2014-05-12
ZA201500790B (en) 2017-04-26
US8933108B2 (en) 2015-01-13
KR20160038079A (ko) 2016-04-06
RS55468B1 (sr) 2017-04-28
PE20141993A1 (es) 2014-12-17
PT2753609T (pt) 2017-02-08
GT201400042A (es) 2015-02-19
NZ621089A (en) 2015-07-31
MX2014002688A (es) 2014-04-14
CA2845766A1 (en) 2013-03-14
AU2013200422C1 (en) 2015-01-15
SG2014013114A (en) 2014-07-30
CN106187942A (zh) 2016-12-07
TW201317221A (zh) 2013-05-01
HRP20170075T1 (hr) 2017-03-24
CY1118585T1 (el) 2017-07-12
BR112014004732A2 (pt) 2017-03-28
CU24303B1 (es) 2018-01-10
US20150336914A1 (en) 2015-11-26
MX345405B (es) 2017-01-30
PL2753609T3 (pl) 2017-05-31
WO2013035047A1 (en) 2013-03-14
US20130245080A1 (en) 2013-09-19
AP2014007462A0 (en) 2014-02-28
ZA201401112B (en) 2016-01-27
CN103781771A (zh) 2014-05-07
TN2014000060A1 (en) 2015-07-01
CO6900147A2 (es) 2014-03-20
EP2753609B1 (en) 2016-11-09
SI2753609T1 (sl) 2017-03-31
MY163301A (en) 2017-09-15

Similar Documents

Publication Publication Date Title
US10251868B2 (en) Benzothiazolone compound
EP2890687B1 (en) Salts of benzothiazolone compound as beta-2-adrenoceptor agonist
HK1242680A1 (en) Salts of benzothiazolone compound as beta-2-adrenoceptor agonist
HK1206015B (en) Salts of benzothiazolone compound as beta-2-adrenoceptor agonist
HK1196351B (en) Benzothiazolone compound
HK1196351A (en) Benzothiazolone compound
NZ621089B2 (en) Benzothiazolone compound

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20201116

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20201116

St.27 status event code: N-4-6-H10-H13-oth-PC1903